Prostate Cancer
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global prostate cancer market intelligence for pharma BD, investors & analysts. Track drug development, clinical trials, and regulatory approvals.
Showing 1–11 of 11 articles
Quick answer
NovaPharmaNews Prostate Cancer hub for FDA covers 11 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA Approves Capivasertib for PTEN-Deficient Prostate Cancer
Pfizer sharpens prostate cancer case with Talzenna win — oncology
New Hormone Regimen Shows Promise for Prostate Cancer Surgery Patients: Study Insights
ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
Candel's Prostate Cancer Drug: Long-Term Data Insights Ahead of FDA Filing
FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Prostate Cancer
ASCO 2026: Key Oncology Data Readouts to Watch
AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs
Francis Medical's Vanquish System Performs First Commercial Prostate Ablation Procedure in Midwest
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.